版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
AimsWhatistheidealHbA1c?LegacyeffectBloodPressure:canwegotoolow?Cholesteroltargets,andtheroleofFibratesWhoshouldhaveaspirin?CaseScenariosWhatdrugstouseaftermetformin?Whentouseinsulinandwhichone?Anythingelse?AimsWhatistheidealHbA1c?LWhatistheidealHbA1cUKPDSdataDCCTandEDICtrialADVANCEACCORDSTENOVADT
WhatistheidealHbA1cUKPDSdHbA1c
cross-sectional,medianvaluesHbA1ccross-sectional,median糖尿病研究最新进展(2011年)课件UKPDS80–LegacyofLong-termGlycaemicControl(30YearFollowUpData)UKPDS80–LegacyofLong-termAftermedian8.5yearspost-trialfollow-up
AggregateEndpoint
1997
2007Anydiabetesrelatedendpoint RRR:
12%
9%
P:
0.029
0.040
Microvasculardisease RRR:
25%
24%
P:
0.0099
0.001Myocardialinfarction RRR: 16% 15%
P:
0.052
0.014All-causemortality RRR: 6% 13%
P:
0.44
0.007RRR=RelativeRiskReduction,P=LogRankLegacyEffectofEarlierGlucoseControlAftermedian8.5yearspost-trACCORDADVANCEandVADT-NoSignificantEffectonMacroVascularOutcomesACCORDADVANCEVADTNo.ofparticipants10,25111,1401791Participantage,years626660Durationofdiabetesatstudyentry,years10811.5HbA1CatBaseline,%8.17.59.4Participantswithpriorcardiovascularevent,%353240Durationoffollow-up,years3.45.06ACCORDADVANCEandVADT-NoSiSummaryofACCORD,ADVANCEandVADT:Outcomes,intensivevs.standardACCORDADVANCEVADTHbA1c,%6.4vs.7.5*6.5vs.7.3*6.9vs.8.4*Deathfromanycause,%
5.0vs.4.0*8.9vs.9.6NADeathfromcardiovascularevent,%
2.6vs.1.8*4.5vs.5.22.1vs.1.7NonfatalMI,%
3.6vs.4.6*2.7vs.2.86.1vs.6.3Nonfatalstroke,%
1.3vs.1.23.8vs.3.82.0vs.3.1Neworworseningnephropathy,%
NA4.1vs.5.2*NAMajor/severehypoglycemia,%
10.5vs.3.5*2.7vs.1.5*21.1vs.9.7*Weightgain,kg3.5vs.0.4*0.0vs.-1.0*NA*p≤0.05
SummaryofACCORD,ADVANCEand糖尿病研究最新进展(2011年)课件ACCORDRetinalConclusionIntensiveglycemiccontrolandintensivecombinationtreatmentofdyslipidemia,butnotintensiveblood-pressurecontrol,reducedtherateofprogressionofdiabeticretinopathy.(FundedbytheNationalHeart,Lung,andBloodInstituteandothers;ClinicalTnumbers,NCT00000620fortheACCORDstudyandNCT00542178fortheACCORDEyestudy.)ACCORDRetinalConclusionIntenADVANCE4.3yearsoffollow-up:Perindopril/indapamideBloodpressurereduced7.1±0.3mmHgsystolicand2.9±0.2mmHgdiastolic(P<0.001).135/75:140/77(baseline145/81)HbA1Cwasreducedby0.61±0.02%after4.3years(P<0.001).GlicazideMRADVANCE4.3yearsoffollow-up:糖尿病研究最新进展(2011年)课件VADTConclusionIntensiveglucosecontrolinpatientswithpoorlycontrolledtype2diabeteshadnosignificanteffectontheratesofmajorcardiovascularevents,death,ormicrovascularcomplications,withtheexceptionofprogressionofalbuminuria(P=0.01)VADTConclusionIntensiveglucoVADTintheContextofthe“NaturalHistory”ofType2DiabetesTime(yearssincediagnosis)HbA1c(%)6.06.57.07.58.08.59.09.512345678910111213141516DrivetheriskforcomplicationsVADTintheContextofthe“NaMeanSystolicBlood-PressureLevelsatEachStudyVisitTheACCORDStudyGroup.NEnglJMed2010;362:1575-1585MeanSystolicBlood-PressureLACCORDBPConclusionInpatientswithtype2diabetesathighriskforcardiovascularevents,targetingasystolicbloodpressureoflessthan120mmHg,ascomparedwithlessthan140mmHg,didnotreducetherateofacompositeoutcomeoffatalandnonfatalmajorcardiovasculareventsACCORDBPConclusionInpatientACCORDlipidConclusionThecombinationoffenofibrateandsimvastatindidnotreducetherateoffatalcardiovascularevents,nonfatalmyocardialinfarction,ornonfatalstroke,ascomparedwithsimvastatinaloneTheseresultsdonotsupporttheroutineuseofcombinationtherapywithfenofibrateandsimvastatintoreducecardiovascularriskinthemajorityofhigh-riskpatientswithtype2diabetesACCORDlipidConclusionThecomHazardRatiosforthePrimaryOutcomeinPrespecifiedSubgroupsTheACCORDStudyGroup.NEnglJMed2010;362:1563-1574HazardRatiosforthePrimary糖尿病研究最新进展(2011年)课件DiabetesandAspirinGuidanceYesinsecondarypreventionPrimarypreventionshouldbeonanindividualbasiswithconsiderationofthebenefitsandharmsofaspirin,takingintoaccountthepresenceofriskfactorsforvasculardisease(includingconditionssuchasdiabetes)andtheriskofgastrointestinalbleeding..MHRADrugSafetyUpdate.October2009.DiabetesandAspirinGuidanceYDiabetesandAspirinGuidancePrimaryprevention:over50,smoker,treatedforhypertensionandhighcholesterol:yesUnder50withallfactorsandFH:yesfromage40Under50:noOver50non-smokeronlyDM:noOver50treatedforhypertension,andhighcholesterol:probablyyesDiabetesandAspirinGuidancePAspirinandDiabetesTheASCENDStudyisalargemultisitestudyrecruiting10,000patientsover40withtype2diabetesdesignedtoanswerthequestionwhetheraspirinshouldbeprescribedroutinelyindiabeticpatients.(2011)ACCEPT-DItalianstudy5000patients,greaterthan50.(aspirin/placebo)2007startedAspirinandDiabetesTheASCENDNICEGuidelines:GeneralRecommendations
Structureddiabeteseducation,andaimforgoodglucosecontrolearlyoninthediagnosis(metforminearly).TargetHbA1cof6.5%forType2Diabetesingeneral,butavoidpursuinghighlyintensivemanagementoflevelslessthan7%inthosewithlimitedlifeexpectancy5years),especiallyifusingdrugswhichcangeneratehypoglycaemiaBloodpressuretargetoflessthan140/80mmHg(Nolegacyeffect)Simvastatin40mgorequivalentforallpatientswithType2diabetesagedover40,irrespectiveofexperienceofCVdisease.NICEGuidelines:GeneralRecomMonotherapywith1stor2ndGenerationSUswasAssociatedwith24-61%ExcessRiskForAllCauseMortalityComparedwithMetforminMonotherapy(P<0.001)2.01.51.00.51stGenerationsulphonylureasvmetformin2ndGenerationsulphonylureasvmetforminAllrosiglitazone*vmetforminAllpioglitazone*vmetforminAllrosiglitazone*vallpioglitazone*Othercombinations†vmetforminTzoulakietal.,BMJ2009;339:b4731HazardRatio(95%CI)(LogScale)*Anytherapy(monotherapyandcombinations).†OtherdrugsandcombinationsofanyoralantidiabetesdrugsexcludingrosiglitazoneandpioglitazoneModel2resultsMonotherapywith1stor2ndGeACCORD:MortalityHRforIndividualAgents1ACCORDStudyGroup.EffectsofIntensiveGlucoseLoweringinType2Diabetes.NEnglJMed2008;358:2545-592.ACCORDWebcastpresentedattheAmericanDiabetesAssociation,6-10June2008.Availableat:/StoreTemplate/default.aspx?ReturnUrl=%2fDefault.aspx5.Cefalu,WT.NEnglJMed2008;358(24):2633-2635.6.AvandiaSPCMarch2008ACCORD:MortalityHRforIndivA40yearoldSupermarketWorkerA40yearoldladyhasa2yearhistoryoftype2diabetes.Herglycaemiccontrolisconsistentlypoor.Sheisanex-smokerwithaBMIof49.HercurrentmedicationincludesAspirin75mgOD,Lisinopril20mgOD,Simvastatin20mgOD,Metformin850mgBD.ExaminationrevealBPof175/70mm/hg,peripheralpulsesarenormalwithnoevidenceofneuropathy.Fundoscopyrevealsearlybackgroundretinopathy.Hba1c-8.5%TC-5.7mmol/lLDL-C-3.5mmol/lHDL-C-0.9mmol/lPlasmaTG-2.6mmol/lU/E-NormalLFT-NormalMicroalbuminuriascreen-positiveHowwouldyoufurthermanagethispatient?A40yearoldSupermarketWorkPATIENTMRSX78type2DMBMI28HbA1C8.5%,nocomplicationsMetforminintolerant?MetforminMRBP145/89,NormalACR,Chol6.5,Hdl1.3SUs,PioGlitazone,or(Sita)gliptinTargetHbA1c?PATIENTMRSX78type2DMBMI糖尿病研究最新进展(2011年)课件糖尿病研究最新进展(2011年)课件OPTionsBMI>35gliptin?Exenatide,avoidsulphonylureasearlyElderlyavoidsulphonylureasearly,aimforreasonablecontrolHbA1c7.5%BMI<30SusafterMetforminBMI30-35age,renalfunction,weightchanges,?SU,gliptinorPioglitazonesecond.KnownIHDconsiderPioglitazoneaftermetforminunlessheartfailureOPTionsBMI>35gliptin?ExenInsulinCostsMixtures:HumanversusanaloguesNoevidenceofdifference,?IncreasedriskofHypoglycaemia.90%oftype2patientsdoaswelloncheaperhumanmixtureSAVINGS:100patientsaround£15/month/patient=£20000peryearInsulinCostsMixtures:InsulinsandCostsNighttimeinsulin:NPH-noevidenceofdifferenceincontrol,weightgain,?Increasedhypoglycaemia£20permonthdifference:100patients£24,000perannumInsulinsandCostsNighttimeiAmberyPetal.PosterpresentedatDiabetesUKannualprofessionalconference,2005.P120.Approximately60%ofMonotherapyPatientsareMissingGlycaemicTargetsHbA1c<7%HbA1c710%HbA1c>10%40%7%53%AmberyPetal.PosterpresentAimsWhatistheidealHbA1c?LegacyeffectBloodPressure:canwegotoolow?Cholesteroltargets,andtheroleofFibratesWhoshouldhaveaspirin?CaseScenariosWhatdrugstouseaftermetformin?Whentouseinsulinandwhichone?Anythingelse?AimsWhatistheidealHbA1c?LWhatistheidealHbA1cUKPDSdataDCCTandEDICtrialADVANCEACCORDSTENOVADT
WhatistheidealHbA1cUKPDSdHbA1c
cross-sectional,medianvaluesHbA1ccross-sectional,median糖尿病研究最新进展(2011年)课件UKPDS80–LegacyofLong-termGlycaemicControl(30YearFollowUpData)UKPDS80–LegacyofLong-termAftermedian8.5yearspost-trialfollow-up
AggregateEndpoint
1997
2007Anydiabetesrelatedendpoint RRR:
12%
9%
P:
0.029
0.040
Microvasculardisease RRR:
25%
24%
P:
0.0099
0.001Myocardialinfarction RRR: 16% 15%
P:
0.052
0.014All-causemortality RRR: 6% 13%
P:
0.44
0.007RRR=RelativeRiskReduction,P=LogRankLegacyEffectofEarlierGlucoseControlAftermedian8.5yearspost-trACCORDADVANCEandVADT-NoSignificantEffectonMacroVascularOutcomesACCORDADVANCEVADTNo.ofparticipants10,25111,1401791Participantage,years626660Durationofdiabetesatstudyentry,years10811.5HbA1CatBaseline,%8.17.59.4Participantswithpriorcardiovascularevent,%353240Durationoffollow-up,years3.45.06ACCORDADVANCEandVADT-NoSiSummaryofACCORD,ADVANCEandVADT:Outcomes,intensivevs.standardACCORDADVANCEVADTHbA1c,%6.4vs.7.5*6.5vs.7.3*6.9vs.8.4*Deathfromanycause,%
5.0vs.4.0*8.9vs.9.6NADeathfromcardiovascularevent,%
2.6vs.1.8*4.5vs.5.22.1vs.1.7NonfatalMI,%
3.6vs.4.6*2.7vs.2.86.1vs.6.3Nonfatalstroke,%
1.3vs.1.23.8vs.3.82.0vs.3.1Neworworseningnephropathy,%
NA4.1vs.5.2*NAMajor/severehypoglycemia,%
10.5vs.3.5*2.7vs.1.5*21.1vs.9.7*Weightgain,kg3.5vs.0.4*0.0vs.-1.0*NA*p≤0.05
SummaryofACCORD,ADVANCEand糖尿病研究最新进展(2011年)课件ACCORDRetinalConclusionIntensiveglycemiccontrolandintensivecombinationtreatmentofdyslipidemia,butnotintensiveblood-pressurecontrol,reducedtherateofprogressionofdiabeticretinopathy.(FundedbytheNationalHeart,Lung,andBloodInstituteandothers;ClinicalTnumbers,NCT00000620fortheACCORDstudyandNCT00542178fortheACCORDEyestudy.)ACCORDRetinalConclusionIntenADVANCE4.3yearsoffollow-up:Perindopril/indapamideBloodpressurereduced7.1±0.3mmHgsystolicand2.9±0.2mmHgdiastolic(P<0.001).135/75:140/77(baseline145/81)HbA1Cwasreducedby0.61±0.02%after4.3years(P<0.001).GlicazideMRADVANCE4.3yearsoffollow-up:糖尿病研究最新进展(2011年)课件VADTConclusionIntensiveglucosecontrolinpatientswithpoorlycontrolledtype2diabeteshadnosignificanteffectontheratesofmajorcardiovascularevents,death,ormicrovascularcomplications,withtheexceptionofprogressionofalbuminuria(P=0.01)VADTConclusionIntensiveglucoVADTintheContextofthe“NaturalHistory”ofType2DiabetesTime(yearssincediagnosis)HbA1c(%)6.06.57.07.58.08.59.09.512345678910111213141516DrivetheriskforcomplicationsVADTintheContextofthe“NaMeanSystolicBlood-PressureLevelsatEachStudyVisitTheACCORDStudyGroup.NEnglJMed2010;362:1575-1585MeanSystolicBlood-PressureLACCORDBPConclusionInpatientswithtype2diabetesathighriskforcardiovascularevents,targetingasystolicbloodpressureoflessthan120mmHg,ascomparedwithlessthan140mmHg,didnotreducetherateofacompositeoutcomeoffatalandnonfatalmajorcardiovasculareventsACCORDBPConclusionInpatientACCORDlipidConclusionThecombinationoffenofibrateandsimvastatindidnotreducetherateoffatalcardiovascularevents,nonfatalmyocardialinfarction,ornonfatalstroke,ascomparedwithsimvastatinaloneTheseresultsdonotsupporttheroutineuseofcombinationtherapywithfenofibrateandsimvastatintoreducecardiovascularriskinthemajorityofhigh-riskpatientswithtype2diabetesACCORDlipidConclusionThecomHazardRatiosforthePrimaryOutcomeinPrespecifiedSubgroupsTheACCORDStudyGroup.NEnglJMed2010;362:1563-1574HazardRatiosforthePrimary糖尿病研究最新进展(2011年)课件DiabetesandAspirinGuidanceYesinsecondarypreventionPrimarypreventionshouldbeonanindividualbasiswithconsiderationofthebenefitsandharmsofaspirin,takingintoaccountthepresenceofriskfactorsforvasculardisease(includingconditionssuchasdiabetes)andtheriskofgastrointestinalbleeding..MHRADrugSafetyUpdate.October2009.DiabetesandAspirinGuidanceYDiabetesandAspirinGuidancePrimaryprevention:over50,smoker,treatedforhypertensionandhighcholesterol:yesUnder50withallfactorsandFH:yesfromage40Under50:noOver50non-smokeronlyDM:noOver50treatedforhypertension,andhighcholesterol:probablyyesDiabetesandAspirinGuidancePAspirinandDiabetesTheASCENDStudyisalargemultisitestudyrecruiting10,000patientsover40withtype2diabetesdesignedtoanswerthequestionwhetheraspirinshouldbeprescribedroutinelyindiabeticpatients.(2011)ACCEPT-DItalianstudy5000patients,greaterthan50.(aspirin/placebo)2007startedAspirinandDiabetesTheASCENDNICEGuidelines:GeneralRecommendations
Structureddiabeteseducation,andaimforgoodglucosecontrolearlyoninthediagnosis(metforminearly).TargetHbA1cof6.5%forType2Diabetesingeneral,butavoidpursuinghighlyintensivemanagementoflevelslessthan7%inthosewithlimitedlifeexpectancy5years),especiallyifusingdrugswhichcangeneratehypoglycaemiaBloodpressuretargetoflessthan140/80mmHg(Nolegacyeffect)Simvastatin40mgorequivalentforallpatientswithType2diabetesagedover40,irrespectiveofexperienceofCVdisease.NICEGuidelines:GeneralRecomMonotherapywith1stor2ndGenerationSUswasAssociatedwith24-61%ExcessRiskForAllCauseMortalityComparedwithMetforminMonotherapy(P<0.001)2.01.51.00.51stGenerationsulphonylureasvmetformin2ndGenerationsulphonylureasvmetforminAllrosiglitazone*vmetforminAllpioglitazone*vmetforminAllrosiglitazone*vallpioglitazone*Othercombinations†vmetforminTzoulakietal.,BMJ2009;339:b4731HazardRatio(95%CI)(LogScale)*Anytherapy(monotherapyandcombinations).†OtherdrugsandcombinationsofanyoralantidiabetesdrugsexcludingrosiglitazoneandpioglitazoneModel2resultsMonotherapywith1stor2ndGeACCORD:MortalityHRforIndividualAgents1ACCORDStudyGroup.EffectsofIntensiveGlucoseLoweringinType2Diabetes.NEnglJMed2008;358:2545-592.ACCORDWebcastpresentedattheAmericanDiabetesAssociation,6-10June2008.Availableat:/StoreTemplate/default.aspx?ReturnUrl=%2fDefault.aspx5.Cefalu,WT.NEnglJMed2008;358(24):2633-2635.6.AvandiaSPCMarch2008ACCORD:MortalityHRforIndivA40yearoldSupermarketWorkerA40yearoldladyhasa2yearhistoryoftype2diabetes.Herglycaemiccontrolisconsistentlypoor.Sheisanex-smokerwithaBMIof49.Hercurren
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 《夜航船》逐章(节)解读
- 教育资源共享平台建设搭建教育资源共享平台促进资源共享和互助三篇
- 项目财务风险评估与项目资金结构优化三篇
- 开展市场调研把握市场动态三篇
- 提高门诊收费与费用核算的透明度三篇
- 口腔科医生月度口腔检查总结
- 加强市场竞争情报收集能力制定行业前瞻性计划三篇
- 家具店面整体转租合同
- 合同范本盖章
- 篮球机构退费合同
- 第32练 《山居秋暝》《菩萨蛮(小山重叠金明灭)》《菩萨蛮•书江西造口壁》《青玉案•元夕》理解性默写-2024年高考语文古诗文名句名篇默写每日一练(统编版)原卷版
- 全球民用降落伞市场:现况分析与预测(2024-2030)
- 卫生巾自动售卖机
- 医院院长办公会议事规则
- 健康素养66条健康教育知识讲座课件
- 居危思危 国家安全与乡村治理
- 初中数学分层教学研究的中期报告
- 古代汉语期末考试试题及答案
- 应届毕业生实习期综合评定表
- 广西北海市2022-2023学年二年级上学期语文期末试卷(含答案)
- 声纳原理课件
评论
0/150
提交评论